All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Wavelength-Pharmaceuticals-Insert

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

All Data

Filters

refresh

×

FILTER DATA :

Country

News Type

Company

Product Type

Deal Size

refresh

Product Type

Companies

9 Meters Biopharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

9 Meters Biopharma, Inc. Doses the First Patients in Phase 1b/2a Clinical Trial in Short Bowel Syndrome

Contact the Supplier

Lead Product(s): NM-002

Therapeutic Area: Gastroenterology Product Name: NM-002

Highest Development Status: Phase I/ Phase II Product Type: Peptide

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 21, 2020

Details:

The Phase 1b/2a clinical trial is an open-label, single-center study evaluating the safety and tolerability of three escalating doses of NM-002 in adult patients with SBS.

9 Meters Biopharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

9 Meters Biopharma, Inc. Initiates Phase 1b/2a Clinical Trial in Short Bowel Syndrome

Contact the Supplier

Lead Product(s): NM-002

Therapeutic Area: Gastroenterology Product Name: NM-002

Highest Development Status: Phase I/ Phase II Product Type: Peptide

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 24, 2020

Details:

The Phase 1b/2a clinical trial of NM-002 is an open-label, single-center study evaluating the safety and tolerability of three escalating doses of NM-002 in adult patients with SBS.